NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study

被引：0

作者：

Gregorc, V. ^{[1
]}

Ceresoli, G. L. ^{[2
]}

Zucali, P. A. ^{[2
]}

De Braud, F. G. ^{[3
]}

Bajetta, E. ^{[4
]}

Santoro, A. ^{[2
]}

Vigano, M. G. ^{[1
]}

Cappio, F. Caligaris ^{[1
]}

Lambiase, A. ^{[5
]}

Bordignon, C. ^{[5
]}

机构：

[1] Ist Sci San Raffaele, Dept Oncol, Milan, Italy

[2] Ist Clin Humanitas, Dept Oncol, Milan, Italy

[3] Ist Europeo Oncol, Clin Pharmacol & New Drugs Unit, Milan, Italy

[4] IRCCS Fdn, Ist Nazl Tumori, Dept Oncol, Milan, Italy

[5] MolMed, Clin Dev, Milan, Italy

来源：

EJC SUPPLEMENTS | 2009年 / 7卷 / 02期

关键词：

D O I：

10.1016/S1359-6349(09)71724-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：509 / 509

页数：1

共 50 条

[21] Phase II study of two doses of NGR-hTNF, a vascular targeting agent (VTA), combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens [J].

Sobrero, A. F. ;

Pessino, A. ;

Andretta, V. ;

Bennicelli, E. ;

Fornarini, G. ;

Caprioni, F. ;

Comandini, D. ;

Orsino, L. ;

Lambiase, A. ;

Bordignon, C. .

EJC SUPPLEMENTS, 2009, 7 (02) :341-341

[22] Phase II study of NGR-hTNF, a vascular targeting agent, in combination with doxorubicin in patients with relapsed small cell lung cancer (SCLC) [J].

Gregorc, V. ;

Novello, S. ;

Santoro, A. ;

Grossi, F. ;

Levra, M. Giaj ;

Cavina, R. ;

Vigano, M. ;

Caligaris-Cappio, F. ;

Lambiase, A. ;

Bordignon, C. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[23] Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy [J].

Santoro, Armando ;

Rimassa, Lorenza ;

Sobrero, Alberto F. ;

Citterio, Giovanni ;

Sclafani, Francesco ;

Carnaghi, Carlo ;

Pessino, Anna ;

Caprioni, Francesco ;

Andretta, Valeria ;

Tronconi, Maria Chiara ;

Finocchiaro, Giovanna ;

Rossoni, Gloria ;

Zanoni, Angela ;

Miggiano, Chiara ;

Rizzardi, Gian-Paolo ;

Traversari, Catia ;

Caligaris-Cappio, Federico ;

Lambiase, Antonio ;

Bordignon, Claudio .

EUROPEAN JOURNAL OF CANCER, 2010, 46 (15) :2746-2752

[24] A phase I study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent (VTA), in combination with cisplatin in patients (pts) with solid tumors [J].

De Braud, F. G. ;

Gregorc, V. ;

De Pas, T. M. ;

Citterio, G. ;

Scalamogna, R. ;

Boselli, S. ;

Giovannini, M. ;

Caligaris-Cappio, F. ;

Lambiase, A. ;

Bordignon, C. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[25] PHASE IB STUDY TO DEFINE THE OPTIMAL LOW DOSE OF NGR-HTNF, A NOVEL VASCULAR TARGETING AGENT (VTA), IN COMBINATION WITH CISPLATIN IN PATIENTS (PTS) WITH SOLID TUMOURS [J].

Gregorc, V. ;

De Braud, F. G. ;

De Pas, T. M. ;

Citterio, G. ;

Scalamogna, R. ;

Boselli, S. ;

Giovannini, M. ;

Caligaris-Cappio, F. ;

Lambiase, A. ;

Bordignon, C. .

ANNALS OF ONCOLOGY, 2008, 19 :160-160

[26] NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 [J].

Gregorc, Vanesa ;

Gaafar, Rabab M. ;

Favaretto, Adolfo ;

Grossi, Francesco ;

Jassem, Jacek ;

Polychronis, Andreas ;

Bidoli, Paolo ;

Tiseo, Marcello ;

Shah, Riyaz ;

Taylor, Paul ;

Novello, Silvia ;

Muzio, Alberto ;

Bearz, Alessandra ;

Greillier, Laurent ;

Fontana, Floriana ;

Salini, Giulia ;

Lambiase, Antonio ;

O'Brien, Mary .

LANCET ONCOLOGY, 2018, 19 (06) :799-811

[27] Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors [J].

Gregorc, Vanesa ;

De Braud, Filippo G. ;

De Pas, Tommaso M. ;

Scalamogna, Roberto ;

Citterio, Giovanni ;

Milani, Alessandra ;

Boselli, Sabrina ;

Catania, Chiara ;

Donadoni, Giovanni ;

Rossoni, Gilda ;

Ghio, Domenico ;

Spitaleri, Gianluca ;

Ammannati, Cristina ;

Colombi, Scialini ;

Caligaris-Cappio, Federico ;

Lambiase, Antonio ;

Bordignon, Claudio .

CLINICAL CANCER RESEARCH, 2011, 17 (07) :1964-1972

[28] Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study [J].

Ikeda, Takaya ;

Takemoto, Shinnosuke ;

Senju, Hiroaki ;

Gyotoku, Hiroshi ;

Taniguchi, Hirokazu ;

Shimada, Midori ;

Dotsu, Yosuke ;

Umeyama, Yasuhiro ;

Tomono, Hiromi ;

Kitazaki, Takeshi ;

Fukuda, Masaaki ;

Soda, Hiroshi ;

Yamaguchi, Hiroyuki ;

Fukuda, Minoru ;

Mukae, Hiroshi .

THORACIC CANCER, 2020, 11 (07) :1972-1978

[29] Patient-reported outcomes (PROs) in the double-blind phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC for previously treated patients with malignant pleural mesothelioma (MPM). [J].

Gregorc, Vanesa ;

Bulotta, Alessandra ;

Vigano, Maria G. ;

Citterio, Giovanni ;

Petrella, Giovanna ;

Brioschi, Elena ;

Ducceschi, Monika ;

Gianni, Luca ;

Colombi, Scialini ;

Rossoni, Gloria ;

Salini, Giulia ;

Savia, Veronica ;

Lambiase, Antonio ;

Bordignon, Claudio .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[30] Patient-reported outcomes (PROs) and impact of lactate dehydrogenase (LDH) levels on outcomes in a phase 3 trial (NGR015) with best investigator choice (BIC) plus or minus NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM) [J].

Gregorc, V. ;

Bulotta, A. ;

Vigano, M. G. ;

Citterio, G. ;

Petrella, G. ;

Brioschi, E. ;

Ducceschi, M. ;

Gianni, L. ;

Colombi, S. ;

Rossoni, G. ;

Salini, G. ;

Savia, V. ;

Lambiase, A. ;

Bordignon, C. .

ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →